1093403-45-2Relevant academic research and scientific papers
The identification of the SIRT1 activator SRT2104 as a clinical candidate
Ng, Pui Yee,Bemis, Jean E.,Disch, Jeremy S.,Vu, Chi B.,Oalmann, Christopher J.,Lynch, Amy V.,Carney, David P.,Riera, Thomas V.,Song, Jeffrey,Smith, Jesse J.,Lavu, Siva,Tornblom, Angela,Duncan, Meghan,Yeager, Marie,Kriksciukaite, Kristina,Gupta, Akanksha,Suri, Vipin,Elliot, Peter J.,Milne, Jill C.,Nunes, Joseph J.,Jirousek, Michael R.,Vlasuk, George P.,Ellis, James L.,Perni, Robert B.
, p. 793 - 797 (2013/12/04)
We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting. 2013 Bentham Science Publishers.
SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS
-
, (2009/01/23)
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
